
Xlue raises $35 million to develop a clinical foundation model
The AMW Read
The funding adds a company-level update to clinical AI, while prospective evidence and the reported evaluation details remain limited.
Xlue raises $35 million to develop a clinical foundation model
Xlue disclosed $35 million in funding for clinical intelligence work and published a technical report on its human health foundation model. The model represents patient trajectories as changing health states and treatment actions. Xlue says it is conducting prospective disease-risk studies across multiple health systems and working with pharmaceutical companies to identify new indications for existing drugs.
The funding adds a new company to the healthcare AI market, where clinical models must establish value through evidence and adoption. Xlue's approach focuses on predicting changes in health and responses to treatment. The company reports that its model outperformed frontier token-based systems in blind third-party evaluations at less than 0.1% of their compute cost. Those results are company-reported; the supplied coverage does not describe the evaluation methods or results in detail.
For builders and investors, the prospective studies offer a way to assess whether the model's predictions hold up in real clinical settings. Xlue also proposes offline trial simulations that compare modeled outcomes under drug treatment and control or standard care. Evidence that such simulations improve cohort selection or trial design would be relevant to drug developers; the reported work does not yet establish those outcomes.